X.an
Cytokine release syndrome
May produce pulmonary infiltrates, pulmonary edem (usually noncardiogenic) or the ARDS picture. See also under capillary leak syndrome, ARDS and NCPE
Causative drugs
6
Alemtuzumab
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
1
Oxaliplatin-based regimens
I.a
I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.e VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.e - Laryngospasm (a.k.a. laryngismus) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis - Anaphylactoid reaction X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) VIII.a VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.e VIII - Central-large-upper airway (incl pharyngeal-nasal) involvement
VIII.e - Laryngospasm (a.k.a. laryngismus) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis - Anaphylactoid reaction X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
1